Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs
Status:
Withdrawn
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
After failure on docetaxel, which has been the standard first line therapy for patients with
metastatic castration-resistant prostate cancer (mCRPC), several treatment options are
currently available. In retrospective studies, resistance has been described to two of the
treatment options, enzalutamide and abiraterone, when a splice variant of the Androgen
Receptor (AR-V7) is present on circulating tumor cells (CTCs). The investigators hypothesize
that patients with AR-V7 positive CTCs do have a meaningful response to cabazitaxel.